<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00239486</url>
  </required_header>
  <id_info>
    <org_study_id>248.515</org_study_id>
    <nct_id>NCT00239486</nct_id>
  </id_info>
  <brief_title>Dose Finding Study of Pramipexole (Sifrol) in Patients With Idiopathic Restless Legs Syndrome (RLS)</brief_title>
  <official_title>Evaluation of the Effect of Different Doses of Pramipexole on Subjective and Objective Symptoms of Idiopathic Restless Legs Syndrome (RLS).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate the efficacy and safety of different doses of&#xD;
      pramipexole (Sifrol) on subjective and objective symptoms of idiopathic Restless Legs&#xD;
      Syndrome (RLS) and also to determine the optimal dose of pramipexole in patients with RLS by&#xD;
      polysomnography and evaluation of clinical improvement.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date>April 2004</completion_date>
  <primary_completion_date type="Actual">April 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in periodic limb movements during time in bed index (PLMI) in the polysomnography (PSG).</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary outcomes of the study were other PSG-derived endpoints (changes in the RLS symptom rating scale (RLSRS), and patient reported outcomes).</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <enrollment>109</enrollment>
  <condition>Restless Legs Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pramipexole</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female 18-80 years&#xD;
&#xD;
          2. Confident diagnosis of RLS according to International RLS Study Group criteria&#xD;
&#xD;
          3. RLS rating scale for severity score &gt;15&#xD;
&#xD;
          4. PLM (during time in bed ) index at least 5 per hour&#xD;
&#xD;
          5. Weekly presence of RLS symptoms within last three months&#xD;
&#xD;
          6. Written Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women of childbearing potential, who do not use adequate protection such as barrier&#xD;
             protection, intrauterine device, or hormonal (oral or subcutaneous) contraception&#xD;
&#xD;
          2. Postmenopausal women less than 6 months after last menses, surgically sterilised,&#xD;
             oophorectomised or hysterectomised less than 3 months after operation and not using&#xD;
             adequate protection&#xD;
&#xD;
          3. Women neither using adequate protection nor being postmenopausal and their partner is&#xD;
             not sterilised at least 6 months post operation or does not use condom&#xD;
&#xD;
          4. Any women not having negative serum pregnancy test at screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim Study Coordinator</last_name>
    <role>Study Chair</role>
    <affiliation>B.I. Finland Ky</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NEURO</name>
      <address>
        <city>Helsinki</city>
        <zip>FIN-00250</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/248/248.515_U04-2112.pdf</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/248/248.515_literature.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>October 14, 2005</study_first_submitted>
  <study_first_submitted_qc>October 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2005</study_first_posted>
  <last_update_submitted>October 31, 2013</last_update_submitted>
  <last_update_submitted_qc>October 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2013</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Restless Legs Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramipexole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

